Treating Feline Non-Regenerative Anemia: Transfusion, ESAs and Supportive Care

Management of feline non-regenerative anemia should address both the immediate consequences of reduced oxygen-carrying capacity and the underlying cause. Supportive treatment may include red blood cell transfusion or erythropoiesis-stimulating agents (ESAs), while iron or vitamin B12 supplementation may be appropriate when deficiency contributes to the anemia. 

Red Blood Cell Transfusion 

RBC transfusion can rapidly increase oxygen-carrying capacity and may be required in cats with severe anemia. Approximately one-third of RBC transfusions in cats are administered for non-regenerative anemia¹. 

Blood compatibility should be addressed before transfusion. Cats should be AB blood typed before their first transfusion, and crossmatching should be performed for subsequent transfusions². Crossmatching in transfusion-naive cats has also been recommended, although it may not be essential for every safe transfusion^3,4. 

The decision to transfuse should therefore be based on the patient’s clinical status and severity of anemia rather than the hematocrit alone. 

Erythropoiesis-Stimulating Agents 

ESAs are commonly used for non-regenerative anemia associated with chronic kidney disease, with good response reported in cats^5,6. Their use in primary bone marrow causes is less clearly established. 

Available recombinant human ESA products include epoetin alfa, epoetin beta, and darbepoetin alfa. Because human and feline erythropoietin share more than 80% homology, recombinant human products can interact with feline erythropoietin receptors¹. 

Darbepoetin has a longer circulating half-life than epoetin. In cats, a reported starting regimen is 1.0 μg/kg once weekly, with frequency reduced to every 2–3 weeks after the target PCV is reached⁶. Epoetin is administered more frequently, with a reported starting dose of 100 units/kg subcutaneously three times weekly¹. 

ESAs require careful monitoring because anti-erythropoietin antibodies can cause secondary pure red cell aplasia. This complication has been reported in up to 8% of cats receiving darbepoetin and 25–45% receiving epoetin. Hypertension, seizures, and iron deficiency are additional reported adverse effects¹. 

In cats with PRCA, ESA therapy may not be beneficial when endogenous erythropoietin concentrations are already elevated. Testing erythropoietin levels before administration may therefore be warranted in selected PRCA cases¹. 

Correct Iron Deficiency 

Cats receiving ESAs or being treated for iron deficiency anemia require iron supplementation. Parenteral iron is preferred when reliable absorption is needed, particularly when malabsorption is present. 

Iron dextran is commonly used, with a reported feline dosage of 10 mg/kg every 3–4 weeks¹. Intramuscular administration is recommended to reduce the risk associated with intravenous iron dextran. 

Oral iron is less expensive and considered the safest form of supplementation. Ferrous sulfate is commonly used at 50–100 mg/cat/day PO, providing 8.8–25 mg of elemental iron. Gastrointestinal upset can occur, and administration with food or calcium may reduce absorption. Oral iron can also reduce absorption of fluoroquinolones and tetracyclines, so administration should be appropriately separated¹. 

Address Cobalamin Deficiency 

Anemia associated with hypocobalaminemia requires vitamin B12 supplementation. Parenteral administration is preferred when malabsorption is involved. 

A reported cyanocobalamin protocol is 250 μg SC once weekly for six weeks, followed by another dose 30 days later, with serum cobalamin reassessed 30 days after the final injection¹. Because serum cobalamin can fall again after supplementation, some cats may require chronic intermittent administration⁷. 

Practical Clinical Takeaway 

Supportive therapy should be matched to the clinical problem. Transfusion can provide rapid improvement in oxygen-carrying capacity, while ESAs may be useful particularly in kidney-associated anemia. Iron and cobalamin supplementation should address documented or suspected deficiencies, with route, monitoring and potential adverse effects considered as part of the treatment plan. 

References 

1. Winzelberg Olson S, Hohenhaus AE. Feline non-regenerative anemia: Diagnostic and treatment recommendations. Journal of feline medicine and surgery. 2019 Jul;21(7):615-31. https://journals.sagepub.com/doi/pdf/10.1177/1098612X19856178 

2. Barfield D, Adamantos S. Feline blood transfusions: a pinker shade of pale. Journal of feline medicine and surgery. 2011 Jan;13(1):11-23. https://journals.sagepub.com/doi/pdf/10.1016/j.jfms.2010.11.006 

3. Weltman JG, Fletcher DJ, Rogers C. Influence of cross‐match on posttransfusion packed cell volume in feline packed red blood cell transfusion. Journal of Veterinary Emergency and Critical Care. 2014 Jul;24(4):429-36. https://doi.org/10.1111/vec.12204 

4. Sylvane B, Prittie J, Hohenhaus AE, Tozier E. Effect of cross-match on packed cell volume after transfusion of packed red blood cells in transfusion-naïve anemic cats. Journal of Veterinary Internal Medicine. 2018 May;32(3):1077-83. https://academic.oup.com/jvim/article-pdf/32/3/1077/66670692/jvim15120.pdf 

5. Chalhoub S, Langston C, Eatroff A. Anemia of renal disease: what it is, what to do and what's new. Journal of feline medicine and surgery. 2011 Sep;13(9):629-40. https://journals.sagepub.com/doi/pdf/10.1016/j.jfms.2011.07.016 

6. Chalhoub S, Langston CE, Farrelly J. The use of darbepoetin to stimulate erythropoiesis in anemia of chronic kidney disease in cats: 25 cases. Journal of veterinary internal medicine. 2012 Mar;26(2):363-9. https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1939-1676.2011.00864.x 

7. Kempf J, Hersberger M, Melliger RH, Reusch CE, Kook PH. Effects of 6 weeks of parenteral cobalamin supplementation on clinical and biochemical variables in cats with gastrointestinal disease. Journal of veterinary internal medicine. 2017 Nov;31(6):1664-72. https://academic.oup.com/jvim/article-pdf/31/6/1664/66668182/jvim14830.pdf